A case of complete response of breast cancer with pulmonary metastases to combination therapy of 5'-DFUR and MPA

This paper presents a case with lung metastases from breast cancer. Complete response was obtained by combined chemoendocrine therapy with 5'-DFUR and MPA. The patient was a 62-year-old female. She underwent a standard radical mastectomy in April, 1988. The primary legion was ER (-) and PgR (-)...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 21; no. 15; p. 2655
Main Authors Senga, O, Miyakawa, M, Hikita, H, Horigome, N, Kouzu, S, Kuwae, K, Hanaoka, T, Yoshida, K
Format Journal Article
LanguageJapanese
Published Japan 01.11.1994
Subjects
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Breast Neoplasms - surgery
Chemotherapy, Adjuvant
Drug Therapy, Combination
Female
Floxuridine - administration & dosage
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - secondary
Mastectomy, Radical
Medroxyprogesterone - administration & dosage
Middle Aged
Remission Induction
Online AccessGet more information

Cover

More Information
Summary:This paper presents a case with lung metastases from breast cancer. Complete response was obtained by combined chemoendocrine therapy with 5'-DFUR and MPA. The patient was a 62-year-old female. She underwent a standard radical mastectomy in April, 1988. The primary legion was ER (-) and PgR (-). Postoperative treatments using CMF and CAF were eventually discontinued owing to profound damage to the bone marrow. An adjuvant chemotherapy with UFT has been employed since. Two years and 7 months later, hemosputum and coughing appeared, and metastases to the lung were revealed. Combined chemoendocrine therapy with 5'-DFUR and MPA was undertaken. A significant decrease in tumor size was observed 3 months after the chemoendocrine therapy was begun, and complete response was obtained at the 8th month. The state has been maintained for one year and 9 months. The use of combined chemoendocrine therapy with 5'-DFUR and MPA in patients for whom intensive chemotherapy is not possible due to damage to bone marrow function is considered effective for its antitumor effects or maintaining patients' quality of life.
ISSN:0385-0684